Origo Biopharma focuses on researching and developing novel therapeutic products that modulate the immune system to treat diseases with significant immuno-inflammatory components, such as cancer and fibrosis. They aim to discover and develop next-generation organ-selective therapeutic products. Recently, Origo Biopharma was acquired by Agomab Therapeutics, although the terms of the transaction were not disclosed. Their drugs target health disorders related to TGF-β signaling dysfunction, offering potential cures for devastating medical conditions.